-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
On April 16, Qilu Pharmaceutical and Peptron jointly announced that the two parties have reached an exclusive license agreement for the latter's antibody-conjugated drug (ADC) targeting MUC1.
MUC1—an emerging target for cancer immunotherapy
MUC1—an emerging target for cancer immunotherapyQilu Pharmaceutical introduced an antibody-conjugated drug targeting MUC1 from Peptron this time.
MUC1 is a highly glycosylated transmembrane protein that plays a vital role in the lubrication and protection of normal epithelial cells.
Studies have found that MUC1 is overexpressed in a variety of human epithelial malignancies, including breast, prostate, ovarian, pancreatic, colon, etc.
According to Peptron's official website, PAb001-ADC is a "first-in-class" antibody conjugate drug targeting MUC1-C.
Picture source: reference [2]
Picture source: reference [2]According to the press release, the cooperation between Peptron and Qilu Pharmaceutical will accelerate the global development of PAb001-ADC, a potentially differentiated antibody conjugate drug.
It is worth mentioning that MUC1 has become one of the emerging targets in the field of cancer immunotherapy.
At least four "license-in" authorization cooperations have been reached in one year
At least four "license-in" authorization cooperations have been reached in one yearThe introduction of innovative drugs from outside has become one of the important ways for Qilu Pharmaceutical to expand its product pipeline.
In February 2021, Qilu Pharmaceuticals obtained the exclusive right to develop and commercialize Cend's drug CEND-1 in Greater China.
In October 2020, Qilu Pharmaceutical obtained the exclusive rights to Quantum Genomics' drug candidate firibastat in China.
In July 2020, Qilu Pharmaceutical obtained the exclusive rights of Sesen Bio's VB4-845 (Vicineum) in Greater China.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
Reference
[1]Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC.
[1]Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC.
[2] Peptron's official website.
[4]Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical.
Retrieved Oct 29, 2020, from https://quantum-genomics.
com/en/press-releases/?ID=ACTUS-0-65617&CLIENT=ACTUS- 0-368
[5] Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China.
Retrieved July 31, 2020, from https://ir.
sesenbio.
com/news-releases/news-release- details/sesen-bio-announces-exclusive-license-agreement-qilu
Retrieved July 31, 2020, from https://ir.
sesenbio.
com/news-releases/news-release- details/sesen-bio-announces-exclusive-license-agreement-qilu
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
